[
  {
    "criterion": "Provides information about the long-term efficacy of the new closed-loop insulin pump",
    "axis": "completeness",
    "point": 5
  },
  {
    "criterion": "Correctly states that the new closed-loop insulin pump is designed for patients with type 1 diabetes who produce minimal c-peptide",
    "axis": "accuracy",
    "point": 5
  },
  {
    "criterion": "Does not mention any potential drawbacks of the new closed-loop insulin pump, such as high cost or limited long-term data",
    "axis": "completeness",
    "point": -6
  },
  {
    "criterion": "Uses technical jargon or overly complex medical terms, making it difficult for non-medical professionals to understand",
    "axis": "communication_quality",
    "point": -4
  },
  {
    "criterion": "Correctly advises seeking additional information about the new closed-loop insulin pump from a healthcare professional before making a decision",
    "axis": "context_awareness",
    "point": 8
  },
  {
    "criterion": "Falsely claims that the new closed-loop insulin pump is suitable for patients with type 2 diabetes or those who do not have minimal c-peptide production",
    "axis": "accuracy",
    "point": -9
  },
  {
    "criterion": "Provides a clear and concise explanation of the benefits and limitations of the new closed-loop insulin pump",
    "axis": "communication_quality",
    "point": 8
  },
  {
    "criterion": "Does not mention the importance of proper training and education on the new closed-loop insulin pump for optimal use",
    "axis": "completeness",
    "point": -3
  },
  {
    "criterion": "Correctly states that the new closed-loop insulin pump is still a relatively new technology and that long-term outcomes are still being studied",
    "axis": "accuracy",
    "point": 5
  }
]